{"id":19809,"date":"2024-12-10T18:33:15","date_gmt":"2024-12-10T17:33:15","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2024\/12\/10\/identification-and-phenotypic-characterization-of-neoantigen-specific-cytotoxic-cd4-t-cells-in-endometrial-cancer\/"},"modified":"2024-12-10T18:33:15","modified_gmt":"2024-12-10T17:33:15","slug":"identification-and-phenotypic-characterization-of-neoantigen-specific-cytotoxic-cd4-t-cells-in-endometrial-cancer","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2024\/12\/10\/identification-and-phenotypic-characterization-of-neoantigen-specific-cytotoxic-cd4-t-cells-in-endometrial-cancer\/","title":{"rendered":"Identification and phenotypic characterization of neoantigen-specific cytotoxic CD4+ T cells in endometrial cancer"},"content":{"rendered":"<div>\n<p>Cancer Immunol Res. 2024 Dec 10. doi: 10.1158\/2326-6066.CIR-24-0514. Online ahead of print.<\/p>\n<p>ABSTRACT<\/p>\n<p>Tumor-reactive CD4+ T cells often accumulate in the tumor microenvironment (TME) in human cancer, but their functions and roles in antitumor responses remain elusive. Here, we investigated the immunopeptidome of HLA class II-positive (HLA-II+) endometrial cancer with an inflamed TME using a proteogenomic approach. We identified HLA-II neoantigens, one of which induced polyclonal CD4+ tumor-infiltrating lymphocyte (TIL) responses. We then experimentally demonstrated that neoantigen-specific CD4+ TILs lyse target cells in an HLA-II-dependent manner. Single cell transcriptomic analysis of the TME coupled with T-cell receptor (TCR) sequencing revealed the presence of CD4+ T-cell clusters characterized by CXCL13 expression. The CXCL13+ clusters contained two subclusters with distinct cytotoxic gene expression patterns. The identified neoantigen-specific CD4+ T cells were found exclusively in one of the CXCL13+ subclusters characterized by granzyme B and CCL5 expression. These results demonstrate the involvement of tumor-reactive CD4+ T cells with cytotoxic function in immune surveillance of endometrial cancer and reveal their transcriptomic signature.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39655805\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20241210123314&amp;v=2.18.0.post9+e462414\">39655805<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-0514\">10.1158\/2326-6066.CIR-24-0514<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2024 Dec 10. doi: 10.1158\/2326-6066.CIR-24-0514. Online ahead of print. ABSTRACT Tumor-reactive CD4+ T cells often accumulate in the tumor microenvironment (TME) in human cancer, but their functions and roles in antitumor responses remain elusive. Here, we investigated the immunopeptidome of HLA class II-positive (HLA-II+) endometrial cancer with an inflamed TME using a &#8230; <a title=\"Identification and phenotypic characterization of neoantigen-specific cytotoxic CD4+ T cells in endometrial cancer\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2024\/12\/10\/identification-and-phenotypic-characterization-of-neoantigen-specific-cytotoxic-cd4-t-cells-in-endometrial-cancer\/\" aria-label=\"Read more about Identification and phenotypic characterization of neoantigen-specific cytotoxic CD4+ T cells in endometrial cancer\">Read more<\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-19809","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/19809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=19809"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/19809\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=19809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=19809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=19809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}